Cellarity, Inc.
- Biotech or pharma, therapeutic R&D
Cellarity is a biotech company that works at the confluence of system biology, high-resolution data and machine learning to uncover novel biology and drivers of disease, thus rewriting the rules of drug discovery to create paradigm changing medicines.
Cellarity's lead program, a small molecule fetal hemoglobin inducer which has shown the potential to be a functional cure in a once-a-day pill in pre-clinical animal models, is set to enter clinical studies in Q2 2025. Preclinical studies also show the molecule to be non-genotoxic, non-cytotoxic, non-oncogenic, and non-teratogenic.
Cellarity's pipeline also includes programs in Myleofibrosis (MF) and a JAK3-BTKi duel inhibitor for immunology indications. In 2023 Cellarity signed a partnership agreement with Novo Nordisk for the development of small molecule MASH therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}